{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T02:41:15Z","timestamp":1778121675396,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.ejca.2016.07.008","type":"journal-article","created":{"date-parts":[[2016,8,15]],"date-time":"2016-08-15T15:32:20Z","timestamp":1471275140000},"page":"75-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals"],"prefix":"10.1016","volume":"66","author":[{"given":"Camille","family":"Tlemsani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Mir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitri","family":"Psimaras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yann-Alexandre","family":"Vano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Escudier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Loirat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Ceccaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Goldwasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Ricard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ejca.2016.07.008_bib1","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006577","article-title":"Anti-VEGF therapies in the clinic","volume":"2","author":"Meadows","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"10.1016\/j.ejca.2016.07.008_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1517\/14728222.2011.641951","article-title":"Targeting the VEGF signaling pathway in cancer therapy","volume":"16","author":"Waldner","year":"2012","journal-title":"Expert Opin Ther Targets"},{"issue":"7","key":"10.1016\/j.ejca.2016.07.008_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102484","article-title":"Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis","volume":"9","author":"Zuo","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ejca.2016.07.008_bib4","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/bcp.12149","article-title":"Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis","volume":"76","author":"Qi","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.ejca.2016.07.008_bib5","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/annonc\/mdn713","article-title":"Management of hypertension in angiogenesis inhibitor-treated patients","volume":"20","author":"Izzedine","year":"2009","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2016.07.008_bib6","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"Maitland","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"10.1016\/j.ejca.2016.07.008_bib7","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.ejca.2016.07.008_bib8","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/02841860903524396","article-title":"Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials","volume":"49","author":"Ranpura","year":"2010","journal-title":"Acta Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2016.07.008_bib9","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJM199602223340803","article-title":"A reversible posterior leukoencephalopathy syndrome","volume":"334","author":"Hinchey","year":"1996","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2016.07.008_bib10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11523-011-0201-x","article-title":"Posterior reversible encephalopathy syndrome induced by anti-VEGF agents","volume":"6","author":"Tlemsani","year":"2011","journal-title":"Target Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2016.07.008_bib11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/qjmed\/hcr139","article-title":"Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment","volume":"105","author":"Seet","year":"2012","journal-title":"QJM"},{"issue":"11","key":"10.1016\/j.ejca.2016.07.008_bib12","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.1161\/STROKEAHA.108.192616","article-title":"Recommendations for imaging of acute ischemic stroke: a scientific statement from the American Heart Association","volume":"40","author":"Latchaw","year":"2009","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.ejca.2016.07.008_bib13","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S1474-4422(13)70255-2","article-title":"Secondary stroke prevention","volume":"13","author":"Hankey","year":"2014","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.ejca.2016.07.008_bib14","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1474-4422(06)70408-2","article-title":"Recent advances in management of transient ischaemic attacks and minor ischaemic strokes","volume":"5","author":"Rothwell","year":"2006","journal-title":"Lancet Neurol"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2016.07.008_bib15","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1007\/s00702-013-1040-y","article-title":"Advances in the management of intracerebral hemorrhage","volume":"120","author":"Kuramatsu","year":"2013","journal-title":"J Neural Transm"},{"issue":"9","key":"10.1016\/j.ejca.2016.07.008_bib16","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1161\/STR.0b013e3181ec611b","article-title":"Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"41","author":"Morgenstern","year":"2010","journal-title":"Stroke"},{"issue":"6","key":"10.1016\/j.ejca.2016.07.008_bib17","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s00280-013-2155-4","article-title":"Bevacizumab and central nervous system (CNS) hemorrhage","volume":"71","author":"Letarte","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.1016\/j.ejca.2016.07.008_bib18","doi-asserted-by":"crossref","DOI":"10.4103\/0028-3886.121909","article-title":"Spectrum of neurological complications in HELLP syndrome","volume":"61","author":"Paul","year":"2013","journal-title":"Neurol India"},{"issue":"8","key":"10.1016\/j.ejca.2016.07.008_bib19","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3109\/14767050903317690","article-title":"Posterior reversible encephalopathy syndrome in a patient with HELLP syndrome complicating a triploid pregnancy","volume":"23","author":"Vijayalakshmi","year":"2010","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"5","key":"10.1016\/j.ejca.2016.07.008_bib20","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1172\/JCI18015","article-title":"Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered?","volume":"111","author":"Luttun","year":"2003","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.ejca.2016.07.008_bib21","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1172\/JCI17189","article-title":"Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia","volume":"111","author":"Maynard","year":"2003","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.ejca.2016.07.008_bib22","doi-asserted-by":"crossref","first-page":"5555","DOI":"10.1210\/jc.2003-030528","article-title":"Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences","volume":"88","author":"Tsatsaris","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ejca.2016.07.008_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0404.2008.01059.x","article-title":"Stroke and cancer: a review","volume":"119","author":"Grisold","year":"2009","journal-title":"Acta Neurol Scand"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804916323103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804916323103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,9]],"date-time":"2018-09-09T06:25:22Z","timestamp":1536474322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804916323103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":23,"alternative-id":["S0959804916323103"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2016.07.008","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2016.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}